Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
BUSINESS
Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
Astellas Pharma is set to capitalize on an eye drug to be acquired through the buyout of Iveric Bio as a “third pillar” of its business that will make up for an anticipated patent cliff of its blockbuster cancer med…
To read the full story
Related Article
- Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
August 8, 2023
- Astellas’ Iveric Bio Acquisition Completed
July 13, 2023
- Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
BUSINESS
- Keytruda Filed for Perioperative Use for Head and Neck Cancer in Japan
March 24, 2025
- Departing Employee Stole Personal Data on 5,200 People: MSD
March 24, 2025
- Santen to Launch Myopia Drug in April; Will Its Private-Care Use Spread in Children?
March 21, 2025
- Otsuka/Taiho Look to Leverage Araris’ Linker Tech to Create 1st-in-Class ADCs
March 21, 2025
- Nippon Kayaku’s Humira Biosimilar Adds nr-axSpA Use
March 21, 2025
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…